[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586099":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":78,"collaborators":81,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":26,"enrollmentInfo":93,"targetDuration":26,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HORIZONS intervention","EXPERIMENTAL","Participants randomized to HORIZONS plus usual care will complete the following:\n\n* Questionnaires at baseline, and weeks 10 and 18\n* Receive the HORIZONS intervention from enrollment and for up to 8 weeks. HORIZONS is an 8-session multidisciplinary, patient-centered intervention that combines medical and psychosocial expertise to enhance self-management and quality of life.\n* Receive usual care as determined by their local clinicians",[13],"Behavioral: HORIZONS Intervention",{"label":15,"type":16,"description":17,"interventionNames":18},"Minimally enhanced usual care","ACTIVE_COMPARATOR","Participants randomized to usual care will complete the following\n\n* Questionnaires at baseline, and weeks 10 and 18 after enrollment\n* Receive a standardized booklet containing evidence-based information on chronic GVHD management and HCT survivorship recommendations as well as receive care as determined by their local oncologists",[19],"Behavioral: Minimally enhanced usual care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","HORIZONS Intervention","Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations",[15],[31],{"name":32,"affiliation":5,"role":33},"Areej El-Jawahri MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Lara Traeger PhD","CONTACT","304-284-3012","ltraeger@miami.edu",{"name":32,"role":37,"phone":41,"phoneExt":26,"email":42},"617-721-4000","ael-jawahri@mgb.org",[44,63],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of Miami Sylvester Comprehensive Cancer Center","RECRUITING","Miami","Florida","33136","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-80.19366,25.77427,{"lat":56,"lon":55},[59,62],{"name":60,"role":37,"phone":61,"phoneExt":26,"email":39},"Lara Traeger, PhD","305-243-5302",{"name":60,"role":33,"phone":26,"phoneExt":26,"email":26},{"facility":5,"status":46,"city":64,"state":65,"zip":66,"country":50,"countryCode":51,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Boston","Massachusetts","02114",{"type":53,"coordinates":68},[69,70],-71.05977,42.35843,{"lat":70,"lon":69},[73,76],{"name":74,"role":37,"phone":75,"phoneExt":26,"email":42},"Areej El-Jawahri","617-724-4000",{"name":77,"role":33,"phone":26,"phoneExt":26,"email":26},"Areej El-Jawahri, MD",{"type":33,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"El-Jawahri, Areej,M.D.","Professor of Medicine",[82],{"name":45,"class":6},"100586099","multidisciplinary-intervention-for-adults-with-chronic-graft-versus-host-disease-100586099",false,"NCT06910969","Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease","Multi-Site Randomized Controlled Trial of A Multidisciplinary Intervention for Adults With Chronic Graft Versus Host Disease","HORIZONS","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) who have undergone allogeneic HCT\n* Have moderate to severe cGVHD based on patient-report\n* Have ability to participate in English or Spanish language group telehealth intervention.\n\nExclusion Criteria:\n\n* Patients with mild cGVHD based on their self-report.\n* Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.\n* Patients with active relapsed disease requiring therapy.","ALL","18 Years",{"count":94,"type":95},350,"ESTIMATED","INTERVENTIONAL",[98],"NA","The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.",[101,102],"Bone Marrow Transplant Complications","Graft-versus-Host Disease",[104,105,106,107,108],"neoplasms","hematologic diseases","neoplasms by site","hematologic neoplasms","graft-versus-host disease","2026-03-01",{"date":111,"type":112},"2026-03-03","ACTUAL",{"date":114,"type":112},"2025-08-13",{"date":116,"type":95},"2030-02-01",{"name":5,"class":6},2]